Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 78,125 Shares of Stock

Key Points

• Guy Archibald Innes, a director of VolitionRx Limited, purchased 78,125 shares at an average price of $0.64, increasing his total ownership by 8.79% to 966,814 shares.
• VolitionRx's stock saw a 1.6% increase to $0.65, with a total volume of 167,946 shares traded, highlighting investor interest.
• Wall Street analysts maintain a Moderate Buy rating on VolitionRx, with target prices ranging from $2.50 to $5.00, indicating positive sentiment toward the company's potential growth.

VolitionRx Limited (NYSE:VNRX - Get Free Report) Director Guy Archibald Innes bought 78,125 shares of the firm's stock in a transaction on Tuesday, August 5th. The stock was purchased at an average cost of $0.64 per share, with a total value of $50,000.00. Following the completion of the transaction, the director directly owned 966,814 shares of the company's stock, valued at approximately $618,760.96. The trade was a 8.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Guy Archibald Innes also recently made the following trade(s):

• On Tuesday, June 3rd, Guy Archibald Innes bought 20,000 shares of VolitionRx stock. The stock was acquired at an average price of $0.54 per share, with a total value of $10,800.00.

VolitionRx Stock Up 0.5%

NYSE:VNRX traded up $0.00 during mid-day trading on Friday, hitting $0.64. 56,031 shares of the stock traded hands, compared to its average volume of 195,362. The business's 50-day moving average price is $0.69 and its 200 day moving average price is $0.59. The company has a market cap of $66.76 million, a PE ratio of -1.78 and a beta of 1.26. VolitionRx Limited has a 12-month low of $0.40 and a 12-month high of $0.94.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Two Sigma Securities LLC purchased a new position in shares of VolitionRx during the fourth quarter worth about $29,000. Northern Trust Corp grew its stake in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after buying an additional 28,579 shares in the last quarter. Lagoda Investment Management L.P. grew its stake in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Millennium Management LLC purchased a new position in VolitionRx in the fourth quarter worth $36,000. Finally, Silverberg Bernstein Capital Management LLC grew its position in VolitionRx by 42.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after acquiring an additional 60,209 shares in the last quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on VNRX shares. D. Boral Capital reiterated a "buy" rating and issued a $5.00 price objective on shares of VolitionRx in a research note on Thursday, July 17th. Jones Trading upgraded VolitionRx to a "strong-buy" rating and set a $3.00 price target for the company in a research report on Tuesday, June 10th. Finally, Wall Street Zen assumed coverage on VolitionRx in a research report on Thursday, May 15th. They issued a "sell" rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $3.50.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.